Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We report on 1,082 cases of malignant lymphomas from the files of the Department of Pathology, Chinese PLA General Hospital, Beijing. We found non-Hodgkin's lymphomas (NHL) in 980 cases (91%) and Hodgkin's disease (HD) in the remaining 102 cases (9%). Among the NHL, the diffuse type was seen in 955 cases (97.4%) and the follicular type in 25 cases (2.6%). Among the diffuse NHL, the pleomorphic type was most frequently found (263 cases or 26.8%), followed in frequency by the mixed small and large cell (163 cases or 16.6%). The large-cell cleaved and noncleaved immunoblastic was found in 139 cases (14.2%), small cleaved cell in 132 cases (13.5%), lymphoblastic convoluted and nonconvoluted in 72 cases (7.3%), the small lymphocytic type in 128 cases (13.1%), plasmacytoid type in 40 cases (4.1%), and Burkitt type in 18 cases (1.8%). Using immunohistocytochemistry, we found T-cell lymphoma in 53% and B-cell lymphoma in 47% of cases. The distinctive differences of malignant lymphomas types between China and Western countries suggest the possibility of a relationship to environmental factors.
 ...
PMID:Malignant lymphomas in Beijing. 146 16

Inflammatory cells, e.g., neutrophils, monocytes, and macrophages are presumed to be a source of circulating phospholipase A in nonpancreatic diseases. Therefore, we investigated in a preliminary study whether serum phospholipase A activity is related to leukocyte counts in 43 patients with hematological diseases. Serum PLA activity was significantly increased in patients with Hodgkin's disease, acute monocytic leukemia, myelofibrosis with myeloid metaplasia, and polycythemia vera when compared with patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute myelogenous leukemia, but did not correlate with total leukocyte counts.
 ...
PMID:Serum phospholipase A in hematological diseases. 292 59

This paper explored the curative effect of combined modality therapy and extended field radiotherapy for early-stage Hodgkin's Lymphoma. 104 cases of early-stage Hodgkin's Lymphoma from Jan 1987 to Dec 2010 in PLA Hospital 307 were retrospectively analyzed, including 76 cases in combined modality therapy group and 28 cases in extended field radiotherapy group, and the long-term efficacy and toxicity of two therapy modalities were evaluated. The results showed that the median survival time of 104 cases was 85.42 months, the complete remission rates of combined modality therapy and extended field radiotherapy groups were 72.4 and 71.4 respectively (P = 0.924); the overall response rates of combined modality therapy and extended field radiotherapy groups were 97.4 and 96.4 respectively (P = 0.779); the 5-year overall survival (OS) rates in the 2 groups were 89.5 and 89.1 respectively, and the 8-year OS rates of the 2 groups were 81.3 and 70.6. No statistical difference was found in above-mentioned 2 groups. Moreover, the 5-year progression free survival (PFS) rates of these 2 groups were 84.2 and 69.0 (P = 0.04), and 8-year PFS rates of these 2 groups were 80.0 and 55.5 (P = 0.04) respectively, the 5-year relapse rates of these 2 groups were 28.1 and 45.6 (P = 0.023) respectively. It is concluded that the combined modality therapy can raise the PFS rate and reduce the relapse rate as compared with extended field radiotherapy for early-stage Hodgkin's Lymphoma, but there is no difference in the overall survival rate between the 2 groups.
 ...
PMID:[Retrospective analysis for 104 cases of early-stage Hodgkin's Lymphoma treated with different modality therapies]. 2254 Oct 90